Skip to Main Content

A Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma

Conditions

Brain and Nervous System | Phase I | Pediatrics

Phase III

What is the purpose of this trial?

Primary Objective:

  • To compare the progression-free survival (PFS) in patients with previously untreated low grade glioma (LGG) among patients with and without NF-1 utilizing two carboplatin containing regimens; carboplatin/vincristine (SOC) versus single agent carboplatin(research).

Secondary Objectives:

  • To compare the quality of life of children and young adults with LGG treated with carboplatin versus carboplatin and vincristine
  • To estimate tumor response rates to each regimen of chemotherapy.
  • To determine toxicity of each regimen.
  • To assess the associations that BRAF mutations have on clinical outcomes.
  • To assess aberrations found through whole exome and RNA sequencing and correlate with clinical outcome.
  • Trial with
    Ann and Robert H. Lurie Children's Hospital of Chicago
  • Start Date
    07/08/2015
  • End Date
    03/31/2020
Trial Image

For more information about this study, contact:

Sharon Huie

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    06/22/2018
  • Study HIC
    #1504015591